# PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

> **NCT03693326** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 70 (estimated)

## Conditions studied

- Cancer
- Lung Cancer Metastatic
- Immunotherapy

## Interventions

- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT03693326
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693326, "PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03693326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*